equecabtagene autoleucel + sintilimab

This combination therapy regimen consists of **equecabtagene autoleucel** (CT103A), a chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA), and **sintilimab**, a monoclonal antibody targeting programmed cell death protein 1 (PD-1). Developed and extensively investigated at Ruijin Hospital (Shanghai Jiaotong University), this approach is designed to treat relapsed or refractory multiple myeloma (RRMM). The equecabtagene autoleucel component utilizes fully human scFv domains to recognize and eliminate BCMA-expressing malignant plasma cells. The addition of sintilimab, a PD-1 checkpoint inhibitor, is intended to counteract the immunosuppressive tumor microenvironment and prevent CAR-T cell exhaustion, thereby enhancing the expansion, persistence, and anti-tumor efficacy of the engineered T cells. Clinical data from Ruijin Hospital and associated multicenter trials suggest that this combination can achieve deep clinical responses, including in patients who have previously relapsed after other BCMA-targeted therapies.

Brand names

Fukesu + Tyvyt

Other names

BCMA CAR-T + PD-1 inhibitorchimeric antigen receptor T cell targeting B-cell maturation antigen + programmed cell death protein 1 inhibitorequecabtagene autoleucel plus sintilimabCT103A plus sintilimabCT-103A plus sintilimabCT 103A plus sintilimab